Resistance to Molecular Therapies for Hepatocellular Carcinoma (Resistance to Targeted Anti-Cancer Therapeutics (13))

This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies. Front Matter....Pages i-xiii Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma....Pages 1-24 Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma....Pages 25-43 Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance....Pages 45-64 Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance....Pages 65-91 Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma....Pages 93-103 Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma....Pages 105-116 Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma....Pages 117-131 Overcoming Treatment Resistance in Hepatocellular Carcinoma: Regorafenib and Lessons from Other Malignancies....Pages 133-142 Back Matter....Pages 143-147 And Future Challenges for Cancer Stem Cell Research in HCCReferences; Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma; Introduction; Lessons from Second-Line Clinical Trials in HCC; Preclinical and Translational Data on Mechanisms of Sorafenib Resistance; Future Perspectives; References; Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma; Introduction; mRECIST Assessment at Baseline; mRECIST Evaluation of Tumor Response; Assessment of Response to Loco-Regional Therapies.--[Source inconnue]